Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 18, 2014 08:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM)

CHICAGO, July 18, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) announced today that DALVANCE (dalbavancin) for injection is now available for use to treat adult patients with acute...
June 17, 2014 09:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present at Upcoming Investor Conferences

CHICAGO, June 17, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that members of the executive team will participate in three upcoming investor conferences. Paul R....
June 04, 2014 17:00 ET | Source: Durata Therapeutics, Inc.

New England Journal of Medicine Publishes Data From Durata Therapeutics' Discover Program

CHICAGO, June 4, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced the Phase 3 data from its DISCOVER program evaluating dalbavancin for the treatment of acute bacterial...
May 23, 2014 16:17 ET | Source: Durata Therapeutics, Inc.

FDA Approves Durata Therapeutics' DALVANCE(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Adults

CHICAGO, May 23, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved DALVANCETM (dalbavancin) for injection...
May 13, 2014 16:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Presents Six Dalbavancin Posters at the 24th Annual ECCMID Meeting

CHICAGO, May 13, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two clinical trials of the company's lead product candidate, dalbavancin, was presented...
May 09, 2014 08:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present at Upcoming Investor Conferences

CHICAGO, May 9, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will be presenting an overview of the Company at two upcoming investor...
May 08, 2014 07:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Reports First Quarter 2014 Financial Results

CHICAGO, May 8, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the quarter ended March 31, 2014. "The first quarter of 2014 ended on a high...
May 02, 2014 08:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present Six Dalbavancin Posters at the 24th Annual ECCMID Meeting

CHICAGO, May 2, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two clinical trials of the company's lead product candidate, dalbavancin, will be...
May 01, 2014 08:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Announce First Quarter 2014 Financial Results on May 8, 2014

CHICAGO, May 1, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) has scheduled its quarterly conference call for Thursday, May 8 at 8:30 a.m. Eastern Time to discuss first quarter 2014...
April 24, 2014 08:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Initiates Enrollment in a Phase 3b Study of Dalvance(TM) in a 1500 mg Single Dose

CHICAGO, April 24, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that it has initiated enrollment of a Phase 3b clinical trial to evaluate the efficacy and safety of...